UTHR
United Therapeutics Corporation NASDAQ Listed Jun 17, 1999$536.59
-2.70%
vs $551.47
Mkt Cap $25.7B
52w Low $274.70
81.3% of range
52w High $596.76
50d MA $565.40
200d MA $497.47
P/E (TTM)
19.3x
EV/EBITDA
13.3x
P/B
3.4x
Debt/Equity
0.0x
ROE
18.8%
P/FCF
24.7x
RSI (14)
37.00
ATR (14)
$12.85
Beta
0.75
50d MA
$565.40
200d MA
$497.47
Avg Volume
510.3K
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
1040 Spring Street · Silver Spring, MD 20910 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 7.00 | 6.32 | -9.7% | 596.76 | +0.4% | -4.6% | -0.7% | +0.9% | +2.1% | -0.4% | — |
| Feb 25, 2026 | TNS | 7.13 | 7.70 | +8.0% | 473.43 | +1.4% | +13.0% | -5.9% | +0.1% | +2.0% | -3.0% | — |
| Oct 29, 2025 | TNS | 6.89 | 7.16 | +3.9% | 415.34 | +0.0% | +9.6% | -0.4% | -1.8% | -1.5% | -0.3% | — |
| Jul 30, 2025 | TNS | 7.29 | 6.41 | -12.1% | 297.56 | -4.0% | -5.2% | -2.6% | +7.1% | -0.6% | +4.2% | — |
| Apr 30, 2025 | TNS | 6.29 | 6.63 | +5.4% | 300.76 | +5.4% | +0.8% | -3.0% | +0.3% | +1.4% | -1.2% | — |
| Feb 26, 2025 | TNS | 6.40 | 6.19 | -3.3% | 357.50 | -3.9% | -10.8% | +1.5% | -1.1% | -3.1% | -0.5% | — |
| Oct 30, 2024 | TNS | 6.43 | 6.39 | -0.6% | 352.80 | +1.1% | +2.4% | +3.5% | +0.0% | +0.7% | +1.6% | — |
| Jul 31, 2024 | TNS | 6.40 | 5.85 | -8.6% | 337.54 | -5.0% | -7.2% | +4.6% | -0.0% | -0.6% | -1.2% | — |
| May 1, 2024 | TNS | 5.65 | 6.17 | +9.2% | 234.33 | +3.7% | +8.9% | +1.2% | +1.7% | -0.7% | +2.2% | — |
| Feb 21, 2024 | TNS | 4.19 | 4.36 | +4.1% | 214.16 | +2.6% | +2.3% | -0.7% | +4.3% | -1.5% | +1.4% | — |
| Nov 1, 2023 | TNS | 5.04 | 5.38 | +6.7% | 222.86 | -5.0% | +0.5% | +1.8% | -1.6% | +1.7% | +1.0% | — |
| Aug 2, 2023 | TNS | 4.51 | 5.24 | +16.2% | 240.13 | +8.3% | +0.3% | -3.7% | +1.9% | +0.6% | -0.4% | — |
| May 3, 2023 | BMO | 4.52 | 4.86 | +7.5% | 228.79 | -3.8% | -4.5% | -1.2% | -0.7% | -1.7% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7 | Wells Fargo | Upgrade | Equal Weight → Overweight | $735 | $596.76 | $599.00 | +0.4% | -4.6% | -0.7% | +0.9% | +2.1% | -0.4% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $574.77 | $576.06 | +0.2% | -0.5% | +1.0% | +0.2% | -0.2% | +0.5% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 31 | BofA Securities | Maintains | Neutral → Neutral | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 30 | TD Cowen | Maintains | Buy → Buy | — | $522.83 | $605.22 | +15.8% | +12.5% | +0.8% | -3.8% | -1.0% | -0.9% |
| Mar 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $524.28 | $529.02 | +0.9% | -0.6% | +2.0% | +1.8% | -1.7% | -1.8% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $544.71 | $539.84 | -0.9% | -2.2% | +0.6% | -0.3% | +1.1% | -1.8% |
| Mar 5 | UBS | Maintains | Buy → Buy | — | $490.21 | $490.00 | -0.0% | -1.1% | -1.4% | +10.7% | +1.3% | +1.7% |
| Feb 26 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $489.69 | $495.01 | +1.1% | +2.7% | +0.2% | -2.6% | -1.5% | -0.2% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $447.45 | $448.00 | +0.1% | +1.5% | -1.1% | +1.1% | +1.2% | +0.5% |
| Oct 30 | RBC Capital | Maintains | Outperform → Outperform | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $445.38 | $445.66 | +0.1% | -1.2% | +0.0% | -1.5% | -0.3% | +0.1% |
| Sep 29 | UBS | Maintains | Buy → Buy | — | $432.66 | $429.18 | -0.8% | -1.9% | -1.2% | +4.5% | +1.2% | +2.2% |
| Sep 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $403.80 | $404.98 | +0.3% | -1.8% | +2.1% | +0.0% | -0.5% | -1.3% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $380.47 | $375.61 | -1.3% | +5.3% | -1.5% | +2.3% | -1.8% | +2.1% |
| Sep 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $380.47 | $375.61 | -1.3% | +5.3% | -1.5% | +2.3% | -1.8% | +2.1% |
| Sep 4 | UBS | Maintains | Buy → Buy | — | $391.45 | $395.60 | +1.1% | -2.8% | +5.3% | -1.5% | +2.3% | -1.8% |
| Sep 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $404.81 | $402.61 | -0.5% | -3.3% | -2.8% | +5.3% | -1.5% | +2.3% |
| Sep 2 | BofA Securities | Maintains | Neutral → Neutral | — | $304.76 | $419.63 | +37.7% | +32.8% | -3.3% | -2.8% | +5.3% | -1.5% |
| Sep 2 | Jefferies | Maintains | Buy → Buy | — | $304.76 | $419.63 | +37.7% | +32.8% | -3.3% | -2.8% | +5.3% | -1.5% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $301.39 | $302.96 | +0.5% | +2.8% | +0.8% | +0.3% | +0.3% | -0.3% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $281.95 | $283.25 | +0.5% | -2.6% | +7.1% | -0.6% | +4.2% | -0.8% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $281.95 | $283.25 | +0.5% | -2.6% | +7.1% | -0.6% | +4.2% | -0.8% |
| Jul 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $300.56 | $300.00 | -0.2% | -0.1% | -1.5% | +0.7% | -1.5% | +1.7% |
| Jul 8 | JP Morgan | Maintains | Overweight → Overweight | — | $290.39 | $290.53 | +0.0% | +1.4% | +2.1% | -0.1% | -1.5% | +0.7% |
| Jun 30 | UBS | Maintains | Buy → Buy | — | $284.27 | $285.75 | +0.5% | +1.1% | +1.2% | +1.5% | -0.2% | -1.4% |
| Jun 11 | BofA Securities | Maintains | Neutral → Neutral | — | $281.36 | $282.01 | +0.2% | -1.7% | +3.5% | -1.0% | +1.8% | -0.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $294.60 | $294.52 | -0.0% | +1.4% | -1.2% | +4.0% | +0.4% | -2.1% |
| May 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| May 1 | BofA Securities | Maintains | Neutral → Neutral | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| May 1 | JP Morgan | Maintains | Overweight → Overweight | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| Apr 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $296.42 | $290.31 | -2.1% | -1.7% | +1.9% | +1.3% | +0.8% | -3.0% |
| Apr 21 | BofA Securities | Upgrade | Underperform → Neutral | — | $284.73 | $285.57 | +0.3% | -0.2% | +3.0% | +0.2% | +1.0% | -1.7% |
| Apr 21 | JP Morgan | Maintains | Overweight → Overweight | — | $284.73 | $285.57 | +0.3% | -0.2% | +3.0% | +0.2% | +1.0% | -1.7% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $318.89 | $318.80 | -0.0% | +1.5% | -1.1% | -3.1% | -0.5% | +0.8% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $362.33 | $363.99 | +0.5% | +1.2% | -0.4% | -0.6% | +0.5% | -0.8% |
| Nov 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $373.97 | $375.78 | +0.5% | +0.0% | +0.7% | +1.6% | +3.8% | +1.3% |
| Oct 31 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | Argus | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | $368.43 | $366.99 | -0.4% | +0.6% | -0.1% | -4.8% | -0.7% | -0.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 210 | $554.63 | $116K | 40,513 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 386 | $553.10 | $213K | 40,723 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 691 | $552.29 | $382K | 41,109 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,797 | $551.28 | $991K | 41,800 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,036 | $550.32 | $1.1M | 43,597 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,113 | $549.13 | $611K | 45,633 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,027 | $548.42 | $1.1M | 46,746 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 542 | $547.12 | $297K | 48,773 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 525 | $546.04 | $287K | 49,315 | -2.70% | — |
| Jun 16, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 173 | $545.18 | $94K | 49,840 | -2.70% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 920 | $553.47 | $509K | 40,513 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 760 | $552.59 | $420K | 41,433 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,180 | $551.57 | $651K | 42,193 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,768 | $550.72 | $974K | 43,373 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 732 | $549.56 | $402K | 45,141 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,459 | $548.53 | $800K | 45,873 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 482 | $547.63 | $264K | 47,332 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 470 | $546.22 | $257K | 47,814 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 809 | $545.51 | $441K | 48,284 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 440 | $543.51 | $239K | 49,093 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 200 | $541.61 | $108K | 49,533 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 205 | $540.43 | $111K | 49,733 | +0.58% | — |
| Jun 15, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 75 | $538.85 | $40K | 49,938 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 598 | $553.76 | $331K | 18,876 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 778 | $553.10 | $430K | 19,474 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 1,144 | $551.91 | $631K | 20,252 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 2,200 | $550.89 | $1.2M | 21,396 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 800 | $549.87 | $440K | 23,596 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 1,616 | $548.64 | $887K | 24,396 | +0.58% | — |
| Jun 15, 2026 | EDGEMOND JAMES | CFO AND TREASURER | Sell | 465 | $547.77 | $255K | 26,012 | +0.58% | — |
8-K · 2.02
!! High
United Therapeutics Corporation -- 8-K 2.02: Earnings Results
United Therapeutics reported first-quarter 2026 earnings on May 6, 2026, providing investors with updated financial performance and operational metrics for the period ended March 31.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nebulized Tyvaso's positive Phase 3 results for IPF treatment validate United Therapeutics' pipeline and could drive significant revenue growth if approved, supporting stock appreciation.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new CPA executive appointment suggests improved financial controls and accounting rigor, which could enhance investor confidence and potentially support stock stability, particularly relevant for smaller-cap companies like SNBR and UTHR.
Mar 12
8-K · 1.01
!! High
United Therapeutics Corp -- 8-K 1.01: Material Agreement
United Therapeutics authorized a $2 billion share repurchase program and immediately entered into accelerated share repurchase agreements with Citibank, signaling management confidence and potentially supporting stock prices through reduced share count.
Mar 9
8-K · 7.01
! Medium
United Therapeutics Corp -- 8-K 7.01: Regulation FD Disclosure
United Therapeutics will host a webcast at 8:30 a.m. to present ADVANCE OUTCOMES trial results, potentially providing investors with significant clinical data regarding a key pipeline program.
Mar 2
8-K
Mannkind Corporation -- 8-K Filing
MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.
Feb 26
8-K
United Therapeutics Corp -- 8-K Filing
United Therapeutics achieved record $3.18 billion in 2025 revenues, representing 11% year-over-year growth, signaling strong commercial momentum across its product portfolio for investors.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors Llc | 2,630,000 | $1.6B | Added | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 2,003,742 | $1.2B | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,957,539 | $1.2B | New | Mar 2026 |
| 4 | Renaissance Technologies Llc | 1,787,019 | $1.1B | Reduced | Mar 2026 |
| 5 | Janus Henderson Group Plc | 866,930 | $514M | New | Mar 2026 |
| 6 | Aqr Capital Management Llc | 826,226 | $486M | Reduced | Mar 2026 |
| 7 | Morgan Stanley | 778,550 | $379M | Reduced | Dec 2025 |
| 8 | Invesco Ltd. | 608,367 | $361M | — | Mar 2026 |
| 9 | Fmr Llc | 528,346 | $313M | Added | Mar 2026 |
| 10 | Assetmark, Inc | 634,956 | $309M | Reduced | Dec 2025 |
| 11 | Deerfield Management Company, L.p. | 457,000 | $271M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 436,566 | $259M | Added | Mar 2026 |
| 13 | Citadel Advisors Llc | 360,643 | $214M | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 329,148 | $195M | Reduced | Mar 2026 |
| 15 | Swedbank Ab | 327,122 | $194M | Added | Mar 2026 |
| 16 | Acadian Asset Management Llc | 300,204 | $178M | Added | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 291,621 | $172M | Added | Mar 2026 |
| 18 | Franklin Resources Inc | 277,983 | $165M | Added | Mar 2026 |
| 19 | First Trust Advisors Lp | 270,578 | $160M | Added | Mar 2026 |
| 20 | Pictet Asset Management Holding Sa | 306,837 | $150M | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$25.70B
Enterprise Value
$24.15B
P/E (TTM)
19.26x
Forward P/E
18.27x
PEG Ratio
1.16x
P/B
3.35x
P/S
8.08x
P/FCF
24.70x
EV/EBITDA
13.27x
Shares Out
47.9M
Financials (TTM)
Revenue
$3.18B
Net Income
$1.33B
EBITDA
$1.82B
Free Cash Flow
$1.04B
Op Cash Flow
$1.56B
EPS Basic
$30.13
EPS Diluted
$27.86
EPS Forward
$29.37
Gross Margin
87.9%
Op Margin
46.9%
Net Margin
41.9%
Balance Sheet
Total Assets
$7.88B
Total Liab.
$783.8M
Total Equity
$7.10B
Cash
$1.56B
LT Debt
$0
Book Value/Sh
$160.19
Debt/Equity
0.00x
Current Ratio
6.60
Quick Ratio
6.28
Returns & Growth
ROE
18.8%
ROA
16.9%
ROIC
15.9%
Rev Growth YoY
+10.6%
EPS Growth YoY
+14.0%
Price Returns
2W
-3.3%
1M
-2.5%
3M
+10.5%
6M
+14.6%
12M
+74.6%
Technicals
52W High
$596.76
52W Low
$274.70
50d MA
$565.40
200d MA
$497.47
RSI (14)
37.00
ATR (14)
$12.85
Beta
0.75
Avg Volume
510K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$610.67
High
$700.00
Low
$519.00
Median
$612.50
Data updated apr 27, 2026 7:10am
· Source: financialmodelingprep.com